For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)-;a procedure that removes antibodies from the plasma portion of the blood.
Clinical trial highlights efficacy of imlifidase for kidney transplant recipients
- Post author:
- Post published:October 27, 2024
- Post category:uncategorized